Hematologic Malignancies

Stem Cell Transplantation

Questions discussed in this category

What are your top takeaways in Hematologic Malignancies from ASH 2024?

12 Answers available

Have you used oral vancomycin as prophylaxis for C difficile infection in patients admitted for allogeneic hematopoietic cell transplant?

2 Answers available

Papers discussed in this category

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019-05-30

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Aug 22

Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Oct 23

Oral Vancomycin Prophylaxis for Clostridioides difficile in High-Risk Patients Receiving Systemic Antibiotics: What Exactly Are We Preventing?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020 Aug 22

Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection.

BMJ open, 2023 Sep 13

Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence of infection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019 Jun 27

Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.

Cancer, 2023 Jun 24

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Related Topics in Hematologic Malignancies